We have developed a culture method for the foreign serumfree generation of highly immunostimulatory, CD83
Introduction
Dendritic cells (DC) are professional antigen-presenting cells uniquely capable of stimulating primary T cellmediated immune responses. 1 Advances in culture techniques allow for the generation of large numbers of human DC in vitro from precursors in blood or bone marrow with the help of recombinant cytokines. 2, 3 A number of laboratories are currently investigating the use of cultured DC loaded with tumor antigen in the form of peptides, proteins or genes for the stimulation of cellular immune responses against cancer. [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] Direct transduction of immunostimulatory DC with tumor antigen cDNA may have several advantages when compared with peptides and proteins including sustained intracellular expression of entire protein antigens and concurrent processing of multiple peptide epitopes on both MHC class I and MHC class II molecules. Recently, recombinant replication-deficient E1-substituted adenoviral vectors have been employed for strong gene expression in cultured murine or human dendritic cells. [9] [10] [11] [12] Studies in mice have shown that adenovirus-transduced dendritic cells are capable of inducing tumor antigen-specific CTL in vivo associated with protection against a tumor challenge. [9] [10] [11] These experiments provide the basis for the clinical development of cancer vaccines consisting of antigentransduced DC.
Most protocols for the generation of human DC immunosuppressive effect was confirmed by demonstrating that the stimulatory function of untreated DC could be suppressed in a dose-dependent manner by addition of Adtransduced DC. Furthermore, transwell experiments suggested that direct cell contact was required. Taken together, our results demonstrate the feasibility of efficiently expressing antigens in CD83 + DC using adenoviruses. However, immunosuppressive effects must be considered and carefully studied before Ad-transduced DC are employed for clinical trials. Gene Therapy (2000) 7, 249-254.
employ fetal calf serum (FCS) which might be a problem for clinical application. 5, 6, 12 Furthermore, many investigators have used cultured human DC with an immature phenotype characterized by a comparatively low migratory and immunostimulatory capacity. 5, 6, 12 Our laboratory has developed a two-step culture method for the generation of mature CD83 + human DC from peripheral blood monocytes. 3 Plastic-adherent PBMC are cultured in GM-CSF and IL-4. Developing DC are stimulated on day 7 with a cocktail of proinflammatory cytokines consisting of IL-1␤, TNF-␣, IL-6 and PGE 2 resulting in full maturation within 2 days. Mature DC stably express high levels of costimulatory molecules, display spontaneous migratory activity, and are capable of stimulating strong cellular immune responses in vitro even after withdrawal of cytokines. Of particular importance for clinical use, culture of mature DC is performed only with molecularly defined reagents. Here, we report our studies investigating the possibility of using mature CD83
+ DC for genetic immunization with recombinant adenoviral vectors.
Results
Gene transfer efficiency following transduction of DC with recombinant adenovirus Transduction of DC with recombinant adenovirus was performed by the addition of various amounts of purified virus directly to the culture medium 6 or 24 h after stimulation with the proinflammatory cytokine cocktail. A recombinant adenovirus encoding green fluorescent protein (Ad-EGFP) was used because it allowed for convenient monitoring of gene transfer efficiency. Endogen-ously fluorescent veiled DC could be detected by immunofluorescence microscopy as early as 24 h after the addition of Ad-EGFP. Strongly fluorescent DC were observed 48, 72 and 144 h after transduction (Figure 1a) . Gene transfer efficiency into DC was evaluated by flow cytometric quantification of green fluorescent DC 48 h after the addition of various amounts of Ad-EGFP. As shown in Figure 1b , successful transduction of DC depended on the amount of recombinant adenovirus used. More than 50% of DC were routinely transduced at an MOI (multiplicity of infection) of 300 without significant cytotoxic effects as determined by trypan blue exclusion. At an MOI of greater than 300 noticeable cytotoxicity became apparent resulting in loss of dendritic morphology and cell death. A recombinant adenovirus encoding ␤-galactosidase (Ad-␤gal) was used as a control for all transductions. No endogenous fluorescence was detected in any of the experiments using Ad-␤gal (data not shown).
Phenotype of Ad-transduced DC DC characteristically express large numbers of MHC, adhesion and costimulatory molecules on their cell surface, which promote the induction of cellular immunity. In order to assess whether transduction with recombinant adenovirus would affect the typical DC phenotype, Ad-EGFP-transduced DC (MOI = 300) were stained with selected PE-conjugated mAb and analyzed by flow cytometry. As shown in Figure 2a , green fluorescent DC simultaneously expressed MHC class I, CD58, CD80 and CD83. The expression levels of these surface molecules were similar to untransduced DC (data not shown). Since the recombinant adenovirus might provide a maturational stimulus for DC development, we also transduced DC with Ad-EGFP in the absence of proinflammatory cytokines. However, as shown in Figure 2b , transduction with Ad-EGFP alone does not provide an adequate maturational stimulus, since green fluorescent DC did not express CD83, a characteristic marker for a fully mature DC phenotype.
Function of Ad-transduced DC
Mature DC display an extraordinary capacity to stimulate the proliferation of naive T cells. To evaluate whether transduction with recombinant adenovirus would alter the immunostimulatory function of mature DC, proliferation assays were performed with purified allogeneic CD8 + or CD4 + T cells. DC were transduced with Ad-EGFP, Ad-␤gal or Ad-TRP2, a recombinant adenovirus encoding the melanosomal protein TRP2 at an MOI of 300. Cultured cells were washed 24 h after transduction and co-incubated with purified allogeneic CD8 + or CD4
+ T cells at various DC to T cell ratios. As shown in Figure 3 , Ad-EGFP-transduced DC stimulated proliferation of purified allogeneic CD8 + or CD4 + T cells at low DC to T cell ratios. In contrast to untransduced DC, Ad-EGFP-transduced DC lost their strong immunostimulatory capacity at high DC to T cell ratios. Similar results were obtained when Ad-␤gal-or Ad-TRP2-transduced DC were used (not shown). In subsequent experiments, DC were transduced with various amounts of Ad-EGFP (MOI 3-300) and tested for their capacity to stimulate proliferation of allogeneic CD4 + T cells. As shown in Figure 4 , we observed a dose-dependent immunosuppressive effect of adenoviral transduction at high DC to T cell ratios which correlated with transduction efficiency. We then investigated whether Ad-transduced DC would be able to suppress the immunostimulatory function of untransduced DC. Titrated numbers of Ad-EGFP-transduced DC were added to co-cultures of 10 4 untransduced DC with 2 × 10 5 purified, allogeneic CD4 + or CD8 + T cells directly in 96-well plates. As shown in Figure 5 , the addition of Ad-transduced DC was able
Figure 2 Fluorescent Ad-EGFP-transduced DC strongly express MHC class I, CD58, CD80 and the DC-specific marker CD83 after stimulation with proinflammatory cytokines. Cultured DC were generated from plastic-adherent precursors by culture in medium containing GM-CSF and IL-4 for 7 days. Cells were replated with proinflammatory cytokines, transduced with Ad-EGFP (a). Alternatively, cells were replated without the proinflammatory cytokine cocktail and transduced with Ad-EGFP (b). Nonadherent cells were harvested 48 h later and stained with PE-conjugated mAb as indicated. Flow cytometric analysis was performed to simultaneously detect the expression of the indicated surface markers on green fluorescent DC.
directly to impair the T cell stimulatory capacity of untransduced DC in a dose-dependent manner.
In order to evaluate whether the immunosuppressive effect of Ad-transduced DC was mediated by a soluble factor, we performed transwell experiments. 10 5 Ad-EGFP-transduced or untreated DC were incubated with 10 6 purified allogeneic CD4 + or CD8 + T cells in 24-well plates. Additionally, 10
5 Ad-EGFP-transduced DC were either added directly to 10 5 untreated DC and 10 6 purified allogeneic CD4 + or CD8 + T cells or were placed in transwell chambers in the same well. The semipermeable polycarbonate membrane allows for free exchange of soluble factors but excludes direct cell contact between Ad-EGFP-transduced DC (above) and co-cultures of untransduced DC and allogeneic T cells (below). As shown in Figure 6 , separation of Ad-EGFP-transduced DC in transwell chambers abrogated the immunosuppressive effect.
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Also we performed mixing experiments with transduced DC/T cells in the upper chamber and untransduced DC/T cells below. Even under these circumstances no clear cut soluble immunosuppressive effect was observed. These results suggest that direct contact of Adtransduced DC is needed to inhibit the proliferation of allogeneic CD4
+ or CD8 + T cells in response to untransduced DC.
Discussion
In our experiments we evaluated the possibility of using mature CD83
+ DC for genetic immunization with recombinant adenoviral vectors. The expression of entire antigens in immunostimulatory DC allows for the potential concurrent processing and presentation of multiple MHC class I-restricted epitopes and does not necessarily require prior knowledge of the patient HLA-haplotype or of specific T cell epitopes. Another potential advantage may be the stimulation of antigen-specific MHC class IIrestricted T cell responses. 13 Various gene transfer strategies are currently being evaluated for the expression of antigens in DC. Theoretically, nonviral gene delivery to DC would be clinically preferred thus avoiding the potential pathogenicity and immunogenicity of viral vectors. However, current nonviral gene transfer systems are limited by their low gene transfer efficiency when compared with viral vectors.
14 Therefore, recombinant replication-deficient adenoviral vectors are attractive for clinical application. Importantly, they can be purified to high titers, stored frozen, and used for strong transient expression of antigens in cultured DC. [8] [9] [10] [11] Recently, it has become clear that mature DC are critical for the generation of protective cellular antitumor immunity. 15, 16 Maturation of DC can be induced in culture by incubation of immature DC with proinflammatory cytokines or cross-linking of CD40 on the surface of DC with soluble trimeric CD40L. 3, 15, 17 Mature human DC are uniquely characterized by expression of the surface molecule CD83. Most studies investigating the possibility of inserting genes encoding antigens into human DC in vitro with recombinant adenoviruses have used 'immature' DC derived from PBMC by culture in GM-CSF and IL-4. 5, 6, 12 We observed that transduction of 'immature' DC with recombinant adenovirus did not lead to phenotypic maturation characterized by expression of CD83. Simultaneous stimulation with proinflammatory cytokines, however, resulted in mature DC strongly expressing the encoded antigen. An elegant alternative methodology has recently been reported and involves retargeting of recombinant adenovirus to CD40 molecules expressed on the surface of DC with bispecific mAb. 18 This method overcomes the relative resistance of cultured DC for Admediated gene transfer, which is presumably due to the low or absent expression of the coxsackie adenovirus receptor (CAR) on DC, and greatly reduced the amount of adenovirus needed for efficient transduction. Of importance, cross-linking of CD40 on cultured DC provided a maturational stimulus and led to enhanced allostimulatory capacity of DC.
The observation that adenoviral transduction of mature DC impaired their ability to stimulate proliferation of allogeneic T cells at high DC to T cell ratios was unexpected. Several preparations of recombinant adenovirus and different Ad5-based adenoviral constructs were tested Gene Therapy
Figure 3 Adenoviral transduction of mature DC impairs the ability to stimulate the proliferation of purified CD8
+ or CD4 + T cells at high DC to T cell ratios. Cultured DC were transduced with Ad-EGFP or left untreated and harvested on day 9 as described in Figure 1 . with similar results. Impairment of DC function correlated with the amount of virus used for transduction and, consequently, with the efficiency of transgene expression. The fact that the addition of Ad-transduced DC was able to suppress T cell proliferation in cultures set up with untreated DC and allogeneic T cells in a dose-dependent manner clearly argues in favor of a direct immunosuppressive effect of Ad-transduced DC. Our transwell experiments demonstrate the necessity for direct cell to cell interaction of Ad-transduced DC with mixtures of untransduced DC and responding T cells. The mechanism by which adenoviruses suppress DC function is currently not understood. We did not detect significant morphologic or phenotypic changes following adenoviral transduction of DC. Both untreated and Ad-transduced DC produced similar amounts of IL-12. Furthermore, measurements of IL-2 or IFN-␥ produced by responding T cells in supernatants of mixed lymphocyte reactions did not reveal significant differences between cultures set up with untreated DC or Ad-transduced DC (data not shown). Why do allogeneic T cells fail to proliferate despite high levels of co-stimulatory molecules on DC and requisite cytokines in the culture? Escape from cellular immunity would certainly make a lot of sense from the standpoint of the adenovirus. It is possible that internalization of adenovirus particles into DC leads to intracellular changes resulting in inhibition of T cell stimulatory ability. Alternatively, latent expression of adenoviral genes from the first generation E1-, E3-deleted recombinant adenoviruses used in our experiments may impair DC function. It is also unclear, how Ad-transduced DC can impair the function of untreated DC. These issues will have to be addressed in future experiments.
Taken together, our studies demonstrate that recombinant adenoviruses can be used for strong expression of antigens within cultured, mature, CD83
+ DC and provide the basis for further investigations evaluating the potential clinical utility of this genetic immunization strategy. In preliminary experiments, we have observed that Adtransduced DC can effectively activate melanoma-specific CD8 + CTL in vitro, thus confirming recently published reports. 14, 19 It remains to be determined how the immunosuppressive effects described in this report will impact on the induction of antigen-specific cellular immune responses with Ad-transduced DC.
Materials and methods
Generation of human DC DC were prepared from peripheral blood mononuclear cells (PBMC) as previously described. 3 Briefly, PBMC were incubated (37°C and 5% CO 2 ) in six-well plates (Costar, Bodenheim, Germany) at 10 7 cells/3 ml per well in X-VIVO-15 medium (Bio-Whittaker, Walkersville, MD, USA) containing 1% autologous plasma for 30-40 min. Nonadherent cells were gently washed out and the Figure 1 remaining plastic-adherent cells were further cultured in X-VIVO-15 medium, 800 U/ml GM-CSF (Leukomax; Sandoz, Basel, Switzerland), and 1000 U/ml IL-4 (Strathmann Biotech, Hannover, Germany). Cells were fed every other day (± 1 ml) with X-VIVO-15, 1600 U/ml GM-CSF and 1000 U/ml IL-4. On day 7, nonadherent immature cells were rinsed off the plates and transferred to fresh six-well plates in X-VIVO-15, 800 U/ml GM-CSF, 1000 U/ml IL-4, 10 ng/ml IL-1␤ (Strathmann), 10 ng/ml TNF-␣ (Strathmann), 1000 U/ml IL-6 (Strathmann), and 
Flow cytometric analysis
For immunophenotyping, adenovirus-transduced or untreated DC were washed in cold PBS supplemented with 2% FCS. Cells were stained with mAb specific for human MHC class I, CD58, CD80, CD83 and CD86 (Coulter/Immunotech, Hamburg, Germany) followed by PE-conjugated goat anti-mouse mAb (Jackson Immunoresearch, Westgrove, PA, USA). Surface expression was analyzed using a FACScalibor flow cytometer (Becton Dickinson, Mountain View, CA, USA), data being collected on 5000 to 10 000 viable cells. 
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